Ipsen
Biopharmaceutical company developing medicines for oncology, rare diseases, and neuroscience.
IPN | PA
Overview
Corporate Details
- ISIN(s):
- FR0010259150 (+17 more)
- LEI:
- 549300M6SGDPB4Z94P11
- Country:
- France
- Address:
- 65 QUAI GEORGES GORSE, 92100 BOULOGNE-BILLANCOURT
- Website:
- https://www.ipsen.com/
- Sector:
- Manufacturing
Description
Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-22 07:00 |
Ipsen élargit son portefeuille de produits en développement précoce avec un con…
|
French | 113.7 KB | ||
| 2025-12-22 07:00 |
Ipsen expands early development pipeline with Simcere Zaiming’s innovative anti…
|
English | 119.7 KB | ||
| 2025-12-19 07:00 |
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d…
|
French | 83.8 KB | ||
| 2025-12-19 07:00 |
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease,…
|
English | 66.9 KB | ||
| 2025-12-15 17:30 |
Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son port…
|
French | 74.8 KB | ||
| 2025-12-15 17:30 |
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
|
English | 52.8 KB | ||
| 2025-12-15 11:05 |
Franchissement de seuil
|
French | 266.1 KB | ||
| 2025-12-09 18:00 |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - …
|
English | 70.5 KB | ||
| 2025-12-09 18:00 |
IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025
|
English | 71.0 KB | ||
| 2025-12-08 18:30 |
Ipsen - Novembre 2025 - Information mensuelle relative au nombre total des droi…
|
French | 134.4 KB | ||
| 2025-12-08 18:30 |
Ipsen - November 2025 - Monthly information relative to the total number of vot…
|
English | 155.6 KB | ||
| 2025-12-05 06:58 |
Ipsen apporte des précisions sur l'héritage d'Henri Beaufour
|
French | 69.7 KB | ||
| 2025-12-05 06:58 |
Ipsen provides update on legacy of Henri Beaufour
|
English | 50.4 KB | ||
| 2025-12-04 23:50 |
Communication relative à l'actionnariat d'Ipsen
|
French | 34.2 KB | ||
| 2025-12-01 07:00 |
Ipsen annonce avec une profonde tristesse le décès de Henri Beaufour, membre de…
|
French | 75.6 KB |
Automate Your Workflow. Get a real-time feed of all Ipsen filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ipsen
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ipsen via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-09-04 | N/A | Other | Sell | 850 | 91,374.66 EUR |
| 2024-02-27 | N/A | Other | Buy | 500 | 51,916.20 EUR |
| 2023-07-31 | N/A | Other | Buy | 50,048 | N/A |
Peer Companies
